indiplon

Pfizer has a partnership with Neurocrine Biosciences to develop another sleeping pill, indiplon, that is similar to Lunesta.

Either Pfizer Or Schering-Plough Could Acquire Sepracor 2006

They also sometimes ask companies to run trials of their drug compared to a competitor's drug which the FDA has already approved, as they did with Neurocrine Biosciences, which was asked to run a safety study of their drug indiplon against another FDA approved drug.

No Moving the Goalpoasts, Once Trials Start 2008

Lunesta, the first sleep aid to be approved by the FDA for long-term use, was released last spring; another insomnia drug, Rozerem, was approved last summer, and Pfizer is hoping to gain approval for its sleep aid indiplon, codeveloped by Neurocrine Biosciences, later this year.

Wake-Up Call 2007

Meanwhile, regulars recently demanded more data before approving Neurocrine Biosciences' indiplon sleeping pill, prompting partner Pfizer to drop its deal with Neurocrine last week.

Behavioral Therapy 1, Sleeping Pills 0 Robert Langreth 2006

Shares of Neurocrine Biosciences plunged 25% in late trading after the San Diego-based drugmaker said Pfizer terminated their partnership for sleeping pill indiplon.

Eye On Stocks For Friday, June 23 2006

"This result is ours and investors' worst case scenario--it suggests that the key opportunity for indiplon, early refiling with the FDA and approval of both IR [immediate release] and MR [modified release] forms, is a remote possibility."

Biotech Stocks Hold Steady 2006

But indiplon was recently hit by a Food and Drug Administration setback that could delay its entry to the market until 2008 and reduce its eventual value.

Either Pfizer Or Schering-Plough Could Acquire Sepracor 2006

Analysts have speculated on whether Pfizer would terminate the partnership ever since federal health regulators delayed a decision on indiplon in May.

Sepracor Gains Reflect Pfizer Buyout Speculation 2006

Pfizer opted out of the companies' four-year developmental collaboration on sleeping pill indiplon just a few weeks after the U.S. Food and Drug Administration delayed a decision on the experimental drug.

Biotech Stocks Hold Steady 2006

Late Thursday, Neurocrine announced the end of its drug development deal with Pfizer on indiplon, an experimental drug similar to Sepracor's Lunesta.

Sepracor Gains Reflect Pfizer Buyout Speculation 2006